Enlarge image
Corona vaccine Comirnaty: Also in the future a billion dollar business
Photo: Sina Schuldt / dpa
According to a study, the German pharmaceutical industry will benefit greatly from corona vaccines for years to come.
According to an analysis by the Association of Research-Based Drug Manufacturers (vfa), which is closely associated with the industry, this will result in an additional production value of 16.1 billion euros by 2030.
In the course of vaccine production, there is a volume of work that corresponds to 57,200 jobs over a year.
According to the authors, the economic effects are estimated conservatively.
Thanks to the Corona vaccine Comirnaty, which the Mainz-based manufacturer Biontech played a key role in developing, money in the upper double-digit billion range flowed into the local site from license income alone.
Last year, the German pharmaceutical industry directly and indirectly created gross value added of around 33.6 billion euros, directly employed almost 55,000 people and generated 11.7 billion euros in tax revenue, according to the study.
SPIEGEL had previously reported on it.
"The German pharmaceutical industry is consolidating its role as a future-oriented sector and key industry from which other sectors of the economy are increasingly benefiting," said vfa President Han Steutel.
With the successful application of mRNA technology in vaccine development, a "promising basis for future research breakthroughs" has been laid.
The mRNA technology on which the Biontech vaccine is based is considered a promising method for treating cancer, for example.
The authors write that this results in "enormous economic growth potential" for the pharmaceutical industry.
The mRNA technology is therefore an opportunity for the German pharmaceutical industry, which was once considered the »pharmacy of the world«.
But companies that used to be important, such as Frankfurt-based Hoechst AG or Schering, were broken up or merged.
Companies from Switzerland and the USA are well represented among the world's largest pharmaceutical groups.
mik/dpa-AFX